Concepedia

Ariadna Tibau

AT

22

Publications

1.2K

Citations

17

H-Index

2011

Active since

Affiliations

Hospital de Sant Pau(Current)

Universitat Autònoma de Barcelona

University of Toronto

Princess Margaret Cancer Centre

Brigham and Women's Hospital

Ariadna Tibau is an author at Hospital de Sant Pau specializing in medicine, oncology, and cancer research.

ORCID

Top concepts

Publications per year

2011–2024

22

Publications

22

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Alberto Gallardo, Enrique Lerma, Daniel Escuín et al. · British Journal of Cancer · 2012 · 230 citations · Full text

Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis

Kerstin Noëlle Vokinger, Thomas J. Hwang, Thomas Grischott et al. · The Lancet Oncology · 2020 · 210 citations

, , +14

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

Gloria Peiró, Fernando Ortiz-Martínez, Alberto Gallardo et al. · British Journal of Cancer · 2014 · 90 citations · Full text

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Ariadna Tibau, Consolación Moltó, Alberto Ocaña et al. · JNCI Journal of the National Cancer Institute · 2017 · 85 citations · Full text

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Emilio Alba, Joan Albanell, Juan de la Haba-Rodríguez et al. · British Journal of Cancer · 2014 · 83 citations · Full text

Rows per page

1–5 of 22